Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.
The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback